Background and objectives:Endometrial carcinoma is the predominant gynecologic cancer in industrialized nations and the second most prevalent in developing nations, following cervical carcinoma.Serum biomarkers have the potential to be utilized in the screening, diagnosis, prognosis, and therapy monitoring of endometrial cancer micrometastasis. Trefoil family 3 (TFF3) is known to be excessively produced as a protein in various types of human tumors.The level of the TFF-3 protein is regularly controlled by estrogen, and have been observed in endometrial cancer.

Subjects and methods: This case-control done in Mansoura University, Egypt on a total of 75 patients with 25 age-matched healthy female volunteers as control group and 50 patients were classified according to standard criteria based on data of International Federation of Gynecology and Obstetrics (FIGO) into two groups (non-metastatic endometrial carcinoma and metastatic endometrial carcinoma). Total RNA was extracted from peripheral blood, Real-time PCR for quantification of TFF3 and Serum samples was used to measure TFF3 protein level by ELISA.

Results: Comparison of the control group, patients with non-metastatic endometrial cancer, and patients with metastatic endometrial carcinoma in terms of TFF3 protein level revealed highly significant differences ((0.41 ± 0.15), (3.79 ± 3.05) and (6.09 ± 3.64)) respectively, P-values (all˂ 0.001). AUC values for TFF3 protein level equal 0.654 while TFF3 protein level showed sensitivity percentage of 72% and 60% specificity percent. In the univariable analysis TFF3 protein level gave an odds ratio (ORs) 1.232 at p-values of 0.031while in the multivariable analysis demonstrated an odds ratio (1.212), p-values (0.019).